Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. (RIGL) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Rigel Pharmaceuticals, Inc. (RIGL), featuring income statements, balance sheets, and cash flow data.
Rigel Pharmaceuticals, Inc. (RIGL) Income Statement & Financial Overview
Explore comprehensive income reports for Rigel Pharmaceuticals, Inc. RIGL, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $53.33M | $57.60M | $55.31M | $36.84M |
| Cost of Revenue | $4.41M | $5.79M | $8.03M | $2.81M |
| Gross Profit | $48.92M | $51.81M | $41.10M | $34.03M |
| Gross Profit Ratio | $0.92 | $0.90 | $0.74 | $0.92 |
| R&D Expenses | $8.44M | $5.63M | $6.18M | $5.54M |
| SG&A Expenses | $27.71M | $29.52M | $27.04M | $28.05M |
| Operating Expenses | $36.15M | $35.15M | $33.23M | $33.59M |
| Total Costs & Expenses | $40.56M | $40.94M | $41.25M | $36.39M |
| Interest Income | $591000.00 | $522000.00 | $425000.00 | $552000.00 |
| Interest Expense | $1.85M | $1.96M | $2.06M | $2.03M |
| Depreciation & Amortization | $604000.00 | $604000.00 | $611000.00 | $613000.00 |
| EBITDA | $13.97M | $17.78M | $15.09M | $1.06M |
| EBITDA Ratio | $0.26 | $0.31 | $0.27 | $0.03 |
| Operating Income | $12.77M | $16.66M | $14.06M | $447000.00 |
| Operating Income Ratio | $0.24 | $0.29 | $0.25 | $0.01 |
| Other Income/Expenses (Net) | -$1.26M | -$1.43M | -$1.64M | -$1.48M |
| Income Before Tax | $11.51M | $15.22M | $12.42M | -$1.03M |
| Income Before Tax Ratio | $0.22 | $0.26 | $0.22 | -$0.03 |
| Income Tax Expense | $65000.00 | $881000.00 | $0.00 | $0.00 |
| Net Income | $11.45M | $14.34M | $12.42M | -$1.03M |
| Net Income Ratio | $0.21 | $0.25 | $0.22 | -$0.03 |
| EPS | $0.64 | $0.81 | $0.71 | -$0.06 |
| Diluted EPS | $0.63 | $0.81 | $0.70 | -$0.06 |
| Weighted Avg Shares Outstanding | $17.81M | $17.65M | $17.60M | $17.55M |
| Weighted Avg Shares Outstanding (Diluted) | $18.17M | $17.69M | $17.65M | $17.55M |
Financial performance has remained strong, with revenue growing from $36.84M in Q2 2024 to $53.33M in Q1 2025. Gross profit continued to perform well, with margins at 92% in the latest quarter. Operating income reached $12.77M in Q1 2025, holding a steady 24% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $13.97M. Net income dropped to $11.45M, keeping EPS at $0.64. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan